Trial Profile
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone; Prednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 20 Oct 2022 Status changed from active, no longer recruiting to completed.
- 15 Oct 2021 Planned End Date changed from 1 Apr 2022 to 1 Nov 2021.
- 15 Oct 2021 Planned primary completion date changed from 1 Apr 2022 to 1 Nov 2021.